Ruixin Medical's Next-Generation Angiography-Based FFR System AngioQFA 100 Receives NMPA Approval

Dec 24, 2024 14:39 CST Updated 14:39

RaysightMed

Medical Imaging Product Developer

RaysightMed's New Generation AngioQFA 100 (Coronary Artery Function Measurement System），With the advanced integration of AI and fluid mechanics technology,Take the lead in achieving precise, comprehensive, flexible, and efficient coronary blood supply evaluation.

One analysis, covering multiple vessels, and obtaining results simultaneously.Fractional Flow Reserve (FFR) and Index of Microcirculatory Resistance (IMR), effectively supporting the entire process of interventional surgery PCI.

Four Core Functions, Comprehensive Assessment of Coronary Blood Supply

FFR (Fractional Flow Reserve)It is the gold standard for determining whether coronary artery stenosis causes myocardial ischemia.AngioQFA 100UseA computational fluid dynamics model combined with deep learning rapidly and accurately solves fluid equations to simulate blood flow within vessels, calculating parameters such as blood flow velocity and pressure distribution at various points in the vessel, and then computes FFR.

IMR (Index of Microcirculatory Resistance)An important indicator for evaluating coronary microcirculation function, mainly reflecting coronary microcirculatory resistance.The system can synchronously detect IMR, providing doctors with a more comprehensive assessment of coronary function.

QCA (Quantitative Coronary Angiography)Provided objective and precise vascular morphological data (Such as vessel diameter, degree of stenosis, lesion length, etc.），Reduced the error of manual measurement and provided a reliable basis for the planning and decision-making of coronary intervention treatment.

Surgical Evaluation FunctionCan be based on doctor-designedRevascularization Plan (such as the position, length, diameter of stent placement, etc.)），Expected Effect After Simulation Placement, presenting intuitive images to doctors for formulatingA more scientifically-based decision for surgical planning.

New Wireless Blood Pressure Acquisition Device Optimizes Diagnostic Process

AngioQFA 100 system supports multiple connection methods including wired and wireless for deployment.Adapting to the layout of catheterization labs in different hospitals and integrating into actual diagnostic and treatment processes.。

Real-time Image Integration:Seamless data integration and transmissionPrecise and Timely.
Wireless Pressure Acquisition:No additional wiring required, reducing radiation.Effectively enhance diagnostic performance.
Report available immediately:No additional waiting time required,Race against time,Significantly improve diagnostic efficiency.

Shenzhen Raysightmed Co, Ltd. was established in December 2017. It is a high-tech enterprise in China that focuses on artificial intelligence for cardiovascular and cerebrovascular diseases and precision diagnosis and treatment with surgical robots.

RaysightMed independently developed and launched a series of products including non-invasive functional diagnosis, surgical planning navigation, and vascular interventional surgical robots, committed to providing AI + surgical robot integrated hardware and software intelligent diagnosis and treatment platforms for coronary applications in clinical settings. RaysightMed holds 11 NMPA certificates and 1 EU CE certificate, with over 200 patents applied for and authorized.

RaysightMed has received numerous honors, including the Top 10 in China's AI Medical Imaging in 2021, Top 10 in China's Innovative Medical Devices in 2022, First Prize in the 2022 China Industry-University-Research Cooperation Innovation Achievement Awards, Third Prize in the National Finals of the 2022 China Innovation and Entrepreneurship Competition, and the 2023 Shenzhen Postdoctoral Innovation Practice Base. The company leads key national R&D projects, the Peacock Team program, and special projects from the Shenzhen Medical Academy. RaysightMed demonstrates tremendous growth potential and robust operational capabilities, with its products being utilized in over 800 tertiary hospitals across China. It has successfully completed five rounds of financing led by Matrix Partners, Tencent, SDIC Venture Capital, and others, emerging as a leading potential unicorn in its field.